vimarsana.com

Page 232 - வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients

 E-Mail Credit: University of Cincinnati PORTLAND, OR - A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in JAMA Oncology. While the trial findings did not show a direct patient benefit, they do show that it s possible to safely administer chemotherapy prior to pancreatic cancer surgery. They also pave the way for better treatment testing for this notorious killer. With no symptoms in the early stages, and few effective therapies, pancreatic cancer is the fourth-most deadly cancer type in the United States. According to the American Cancer Society, only 20 percent of pancreatic cancer patients are alive one year after diagnosis. After five years, only about 7 percent are alive.

Bharat Biotech denied permission for simultaneous Phase I, II trials of COVID-19 intranasal vaccine

Bharat Biotech denied permission for simultaneous Phase I, II trials of COVID-19 intranasal vaccine Bharat Biotech is developing the intranasal vaccine in partnership with the Washington University School of Medicine and US-based vaccine maker Ocugen BusinessToday.In | January 20, 2021 | Updated 13:57 IST The non-invasive, single-dose vaccine will be far easier to administer and will work faster and longer, Bharat Biotech had said, and claimed that it will be eco-friendly The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation has denied Bharat Biotech permission to simultaneously conduct Phase I and Phase II trials of its intranasal vaccine for COVID-19. Bharat Biotech is developing the intranasal vaccine in partnership with the Washington University School of Medicine and US-based vaccine maker Ocugen.

For some, GI tract may be vulnerable to COVID-19 infection

For some, GI tract may be vulnerable to COVID-19 infection People with Barrett’s esophagus have SARS-CoV-2 receptors in upper GI tract Washington University School of Medicine Researchers at Washington University School of Medicine in St. Louis have found that patients with Barrett s esophagus may be vulnerable to coronavirus infection from what they swallow. Shown is an organoid built from tissue taken from patients with Barrett s esophagus. The cells resemble intestinal cells rather than normal esophagus cells. The red color notes the presence of a protein called actin that is found in intestinal cells, while the green marks the presence of the TMPRSS2 protein that binds to the SARS-CoV-2 virus.

Blood test can identify COVID patients at high risk of severe complications

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.